InvestSMART

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB)

ALERT: Price-sensitive ASX Announcement for NSB
Current share price for NSB : $0.069 -0.025 (-26.60%)+
Announcement
Release
26 May 2026 9:30AM
Price at Release
$0.094
Full Release
download
Summary
NeuroScientific Biopharmaceuticals Ltd (NSB) has achieved remarkable results from its Special Access Program using its patented StemSmart™ therapy. This program targeted patients with fistulising Crohn's disease, a severe condition often resistant to conventional treatments. The therapy involved mesenchymal stem cells (MSCs) derived from adult human donor bone marrow, and 80% of patients achieved a successful clinical response, demonstrating significant improvement without serious adverse events. Supported by recognized Crohn's disease scoring systems, these results pave the way for a Phase 2 clinical trial in Australia, anticipated to begin in the second half of CY2026. NSB aims to obtain regulatory approval, targeting the global Crohn's disease market, valued at $13.8 billion by 2026, and address other conditions like kidney transplant, lung disorders, and graft-versus-host disease (GvHD).
Key Points
  • NSB reported remarkable clinical results from its Special Access Program using StemSmart™.
  • 80% of patients with fistulising Crohn's disease achieved a successful clinical response.
  • StemSmart™ demonstrated safety and efficacy in patients resistant to conventional treatments.
  • The therapy involves mesenchymal stem cells derived from adult human donor bone marrow.
  • NSB plans a Phase 2 clinical trial for fistulising Crohn's disease in Australia in 2H CY2026.
  • StemSmart™ targets a global market valued at US$13.8 billion by 2026 for Crohn's Disease.
  • NSB's broader strategy includes obtaining regulatory and reimbursement approval for MSC therapy.
  • No serious adverse events were observed during the Special Access Program.
  • The clinical response was supported by internationally recognized scoring systems for Crohn's disease.
  • StemSmart™ also aims to address unmet needs in kidney transplant, lung disorders, and GvHD.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.